2 news items
Quince Therapeutics Updates Pipeline Progress, Eyes Enrollment for Pivotal Phase 3 Trial in Ataxia-Telangiectasia, Reported Q1 EPS Loss of $(0.26), Cash Balance of $67.8M
QNCX
13 May 24
, $1.3 million in stock-based compensation, and $0.4 million change in the fair value of long-term debt due to passage of time, offset
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
QNCX
13 May 24
change in the fair value of long-term debt due to passage of time, offset by a $0.6 million amortization of discount on the company's investments
- Prev
- 1
- Next